The 7F system uses the company’s SelectFlex Technology and is indicated for introducing interventional devices into the neurovasculature.
“Neurovascular access can be extremely challenging. The tortuous anatomy requires flexibility to navigate the tight twists and turns, however, flexible access catheters tend to lack the support and stability required for device delivery once positioned,” said Dr. Pascal Jabbour, The Angela and Richard T. Clark Distinguished Professor of Neurological Surgery and Radiology, Division Chief of Neurovascular Surgery & Endovascular Neurosurgery at Thomas Jefferson University Hospital in Philadelphia, Pennsylvania. “Armadillo provides a one-and-done solution that simplifies access procedures. It is designed to place full control in the hands of the operator as it allows users to transform the catheter from highly trackable to highly supportive as needed throughout the procedure with the simple injection or withdrawal of just 0.2cc of saline.”
The device’s low-profile 7F catheter allows for a biaxial approach to help speed up delicate interventions and reduce the cost of conventional tri-axial configurations, according to the company.
“The Armadillo Neurovascular Access System with SelectFlex™ Technology addresses the shortcomings of currently available neurovascular access catheters. We believe it provides a novel option that allows hospitals to standardize device usage, decrease inventory constraints and reduce cost per procedure,” CEO Jodie Fam said in a news release. “I thank our incredible team for their efforts to achieve this critical milestone. We look forward to building upon Armadillo’s U.S. commercial success as we prepare to expand our international portfolio and deliver this meaningful solution to the European market, and others, in the coming months.”
